| Internal Medicine Associates, Llc | |
|
2841 Debarr Rd Ste 50 Anchorage AK 99508-2945 | |
| (907) 276-2811 | |
| (907) 276-2810 |
| Full Name | Internal Medicine Associates, Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 2841 Debarr Rd Ste 50, Anchorage, Alaska |
| Authorized Official Name and Position | Geronimo Sahagun (MANAGING PHYSICIAN & CEO) |
| Authorized Official Contact | 9072762811 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Internal Medicine Associates, Llc 2841 Debarr Road Suite 50 Anchorage AK 99508-2932 Ph: (907) 276-2811 | Internal Medicine Associates, Llc 2841 Debarr Rd Ste 50 Anchorage AK 99508-2945 Ph: (907) 276-2811 |
| NPI Number | 1043294648 |
|---|---|
| Provider Enumeration Date | 12/06/2005 |
| Last Update Date | 03/25/2019 |
| Medicare PECOS PAC ID | 5496745788 |
|---|---|
| Medicare Enrollment ID | O20040518000154 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043294648 | NPI | - | NPPES |
| MDG284 | Medicaid | AK |
| Provider Name | William Mccray |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1912989781 PECOS PAC ID: 4183614399 Enrollment ID: I20040518000560 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Eric Rodney Tompkins |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1902888688 PECOS PAC ID: 4082604293 Enrollment ID: I20040518000595 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Janice A Koval |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1184606014 PECOS PAC ID: 8921098211 Enrollment ID: I20040518000623 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Gregory D Gerboth |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1407838170 PECOS PAC ID: 7214927516 Enrollment ID: I20040518000760 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Michael Robert Valantas |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1528040292 PECOS PAC ID: 3678555026 Enrollment ID: I20040601001148 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Geronimo Sahagun |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1043292865 PECOS PAC ID: 5799760526 Enrollment ID: I20040625001001 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Douglas B Haghighi |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1780608406 PECOS PAC ID: 7214984186 Enrollment ID: I20071008000031 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Steven B Ingle |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1922070218 PECOS PAC ID: 9931137205 Enrollment ID: I20080811000224 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Marek A Martynowicz |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1962581249 PECOS PAC ID: 8729073093 Enrollment ID: I20091103000744 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Michael E Long |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1821071317 PECOS PAC ID: 3375443088 Enrollment ID: I20171128002585 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Kimberly D Houghton |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1598101503 PECOS PAC ID: 9739483736 Enrollment ID: I20191030000229 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
| Provider Name | Praveen Kumar Roy |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1215958459 PECOS PAC ID: 5698726768 Enrollment ID: I20200609002908 |
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
News Archive
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
A group of researchers from Charité - Universitätsmedizin Berlin have confirmed Germany's first-ever case of animal-to-human transmission involving a specific species of virus known as the 'Seoul virus'.
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Genes that act late in life could explain why women have poorer health than men in older age, according to new research.
› Verified 8 days ago
Alaska Premier Health Alaska Sports Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3300 Arctic Blvd, 101, Anchorage, AK 99503 Phone: 907-561-3488 Fax: 907-562-3488 | |
Alaska Family Care Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4001 Dale Street, Suite 210, Anchorage, AK 99508 Phone: 907-929-5888 Fax: 907-929-5882 | |
Daryl M. Mcclendon, M.d., P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3851 Piper St, Suite U466, Anchorage, AK 99508 Phone: 907-569-1333 Fax: 907-569-1433 | |
Willow Wellness Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3030 Wendys Way Unit A, Anchorage, AK 99517 Phone: 406-253-7924 | |
Douglas Carter Smith, Md Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 17741 Mountainside Village Dr, Anchorage, AK 99516 Phone: 907-345-0728 Fax: 907-345-0728 | |
Summit Family Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2741 Debarr Rd, Suite C308, Anchorage, AK 99508 Phone: 907-272-3366 Fax: 907-272-0269 |